Floatz logo

Amt-151

Endometrial Serous Adenocarcinoma

Multitude Therapeutics Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Endometrial Serous Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BB
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Cediranib
National Cancer Institute (NCI)
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Doxycycline
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC

View all 22 →

Same molecule, other indications

Amt-151 is also rated in:

carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
endometrium adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
endometrial endometrioid adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →